Clinical trial NCT00351715: Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients
Official title: Sublingual Methadone for the Management of Cancer-related Breakthrough Pain in Outpatients: a Phase II Multicenter, Open Label, Feasibility Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Cancer
Pain
Keywords: Sublingual Methadone
Cancer related breakthrough pain
feasibility study
Phase II/open label
Outpatients
Safety/ efficacy
previously receiving opioids
speak English
Lead sponsor: AHS Cancer Control Alberta
Sponsor class: OTHER
Collaborators: name: University of Calgary
First posted: 2006-07-13
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this Phase II study is to determine the feasibility of the dose titration and assessment protocol in the outpatient population before conducting an appropriately powered phase III study. Thus the primary purpose of this study is to determine the proportion of patients who are successfully titrated to an optimal dose of sublingual (Under the tongue) methadone and then studied at that optimal dose with successive episodes of breakthrough pain.


Eligibility criteria: Inclusion Criteria:

* Pain due to cancer or its treatment; controlled baseline pain;
* episodes of breakthrough pain every day that are "4/10" in severity or greater, ;
* ast 10 minutes or longer, and
* are responsive to short acting oral opioids such as morphine or hydromorphone;
* are able to hole a volume of 1.0cc of water under the tongue for a 5-minute period; are able to provide written informed consent;
* are able to fill out the study forms

Exclusion Criteria:

* Severe underlying respiratory disease such that an investigator is wary about the risk of respiratory failure from modest doses of opioid;
* prior sensitivity to methadone;
* currently are being administered methadone;
* have breakthrough pain that in the opinion of the investigator is likely to change within the next seven days (recent or imminent radiation therapy to the main site of pain,
* new chemotherapy or use of an injectable bisphosphonate likely to alter the pain, new use corticosteroids within the past week with a corresponding change in pain, or other interventions judged likely to alter pain);
* are clinically unstable or have a life expectancy of less than one month making completion of the trial unlikely

Primary outcomes:
measure: to demonstrate the feasibility of a novel model to assess sublingual methadone to breakthrough pain in the outpatient setting
timeFrame: 12 months
Secondary outcomes:
measure: to develop a model of PK/PD study of breakthrough pain
timeFrame: Baseline to 5 years
measure: to develop a research tool, the Breakthrough Pain Assessment Tool (BPAT)
timeFrame: Baseline to 5 years
measure: to demonstrate proof of concept
timeFrame: Baseline to 5 years
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Tom Baker Cancer Center
state: Alberta
city: Calgary
country: Canada
facility: Tom Baker Cancer Centre
state: Alberta
Study officials:
affiliation: AHS Cancer Control Alberta
name: Neil Hagen, MD
role: PRINCIPAL_INVESTIGATOR
References: